[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mixed-dyslipidemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mixed-dyslipidemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,43,71,103,135,158,179,198,215],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100568852","a-study-of-bempedoic-acid-in-combination-with-ezetimibe-and-either-rosuvastatin-or-atorvastatin-in-patients-with-primary-hypercholesterolemia-or-mixed-dyslipidemia-100568852",false,"NCT06686615","A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia","Effectiveness and Safety of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: an Observational Study","TRICONOS","Key Inclusion Criteria:\n\n1. Written informed consent to participate\n2. At least 18 years of age\n3. High and very high risk patients as assessed by the physician suffering from documented primary hypercholesterolemia or mixed dyslipidemia at start of bempedoic acid treatment\n4. Patients treated with:\n\n   * bempedoic acid added to ezetimibe and rosuvastatin or atorvastatin,\n   * bempedoic acid plus ezetimibe added to rosuvastatin or atorvastatin,\n   * bempedoic acid plus atorvastatin or rosuvastatin added to ezetimibe\n   * initiation of bempedoic acid, ezetimibe, and atorvastatin or rosuvastatin simultaneously\n\n6\\) Initiation of triple therapy within a maximum of four weeks prior to inclusion 7) An untreated LDL-C value must be available within 5 years prior to the start of the triple therapy. Untreated means that the LDL-C value is not influenced by any lipid lowering therapy at the time of blood collection. Time window for not being treated as specified in the protocol.\n\n8\\) No contraindications exist according to the SmPC of bempedoic acid, the respective statin and ezetimibe as per physicians' assessment 9) No concurrent participation in an interventional study (simultaneous participation in other non-interventional studies is possible) 10) Life expectancy \\> 1 -year\n\nKey Exclusion Criteria:\n\n1. Patients who have received PCSK9i monoclonal antibody treatment in the last 3 months before the start of the triple therapy exposure\n2. Patients who have ever received PCSK9i-siRNA treatment","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","OBSERVATIONAL","Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.",[25,26],"Primary Hypercholesterolemiia","Mixed Dyslipidemia",[28,29],"Primary hypercholesterolemia","Mixed dyslipidemia","RECRUITING","2026-06-09",{"date":33,"type":34},"2026-06-11","ACTUAL",{"date":36,"type":34},"2025-02-12",{"date":38,"type":21},"2028-01-31",{"name":40,"class":41},"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","INDUSTRY",163,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100642965","phase-3-phase-3-clinical-study-evaluating-efficacy-safety-and-tolerability-of-obicetrapib-vs-bempedoic-acid-to-treat-dyslipidemia-in-adults-with-primary-non-familial-hypercholesterolemia-or-mixed-dyslipidemia-at-high-to-very-high-cardiovascular-risk-during-a-treatment-period-of-approximately-84-days-100642965","NCT07614958","Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days","A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on Top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular Risk","MEDICI","Inclusion Criteria:\n\n* Are male or female and ≥18 years of age at Screening (Visit 1);\n* Females may be enrolled if all 3 of the following criteria are met:\n\n  1. Are not pregnant;\n  2. Are not breastfeeding; and\n  3. Do not plan to become pregnant during the study.\n* Have primary non-familial hypercholesterolemia or mixed dyslipidemia and are at high to very high CV risk;\n* Are on stable maximally tolerated lipid-modifying therapy for at least 8 weeks prior to Screening (Visit 1) as an adjunct to a lipid-lowering diet and lifestyle modifications, defined as a maximum tolerated statin dose, with or without ezetimibe and\u002For a monoclonal PCSK9-targeted therapy for at least 4 stable doses prior to Screening (Visit 1);\n* Have a fasting serum LDL-C at Screening (Visit 1) of ≥70 mg\u002FdL (1.81 mmol\u002FL) and \\\u003C130 mg\u002FdL (3.37 mmol\u002FL);\n* Have fasting TGs \\\u003C500 mg\u002FdL (\\\u003C5.7 mmol\u002FL) at Screening (Visit 1); and\n* Have an eGFR ≥30 mL\u002Fmin\u002F1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration equation at Screening (Visit 1).\n\nExclusion Criteria:\n\n* Have current or any previous history of New York Heart Association class III or IV HF or left ventricular ejection fraction \\\u003C30%;\n* Have been hospitalized for HF, with HF as the primary cause of the hospitalization, within 5 years prior to Screening (Visit 1);\n* Have had any of the following clinical events within 3 months prior to Screening (Visit 1): MI; Stroke; Non-elective coronary revascularization; and\u002For Hospitalization for unstable angina and\u002For chest pain.\n* Have uncontrolled severe hypertension;\n* Have a formal diagnosis of definite familial hypercholesterolemia (either homozygous or heterozygous) either through genetic testing on Dutch Lipid Network criteria, Simon Broome, or MedPed;\n* Have active liver disease;\n* Have HbA1c ≥8.0% (≥0.080 hemoglobin fraction) or a fasting glucose ≥270 mg\u002FdL (≥15.0 mmol\u002FL) at Screening (Visit 1);\n* Have a history of a malignancy that required surgery (excluding local and wide local excision), radiation therapy, and\u002For systemic therapy during the 3 years prior to Screening (Visit 1);\n* Have history of full statin intolerance;",{"count":52,"type":21},426,"INTERVENTIONAL",[55],"PHASE3","This Phase 3, randomized, double-blind, active-controlled study evaluates the efficacy and safety of obicetrapib (OBI) compared to bempedoic acid (BPA) in participants with dyslipidemia at high or very high cardiovascular risk. Participants must have elevated low density lipoprotein cholesterol (LDL-C) levels despite receiving maximally tolerated lipid lowering therapy.\n\nThe primary objective is to compare the LDL-C lowering effect of OBI (a CETP inhibitor) against BPA at 12 weeks",[26,58],"Hypercholesterolaemia",[60,61,58,26],"Bempedoic Acid","Obicetrapib","2026-06-05",{"date":31,"type":34},{"date":65,"type":34},"2026-05-06",{"date":67,"type":21},"2027-01",{"name":69,"class":41},"A. Menarini International Licensing S.A.",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":53,"phases":80,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100629436","phase-3-a-study-of-bempedoic-acidezetimibehigh-intensity-statin-in-patients-without-cardiovascular-events-100629436","NCT07474649","A Study of Bempedoic Acid\u002FEzetimibe\u002FHigh-intensity Statin in Patients Without Cardiovascular Events","Effects of Bempedoic Acid\u002FEzetimibe\u002FHigh-intensity Statin on Plaque Regression and Stabilisation of Coronary Atherosclerosis Among Patients Without Cardiovascular Events","Inclusion Criteria:\n\nIn order to be eligible to participate in this trial, a potential participant must meet all of the following criteria:\n\n1. Age ≥18 years\n2. Having provided informed consent for participation in this trial\n3. Lipid-lowering treatment-naïve\n4. Presence of extensive coronary atherosclerosis meeting all of the criteria below:\n\n   * Unequivocal atherosclerosis in ≥5 American Heart Association (AHA) coronary segments (corresponding to a risk equivalent of obstructive coronary artery disease) and coronary artery disease - reporting and data system (CAD-RADS) category 1, 2, or 3\n   * Not expected to be a candidate for revascularisation during the duration of the trial\n   * Untreated LDL-C ≥2.6 mmol\u002FL and ≤4.5 mmol\u002FL (where a diet without pharmacological treatment is considered 'untreated')\n5. Able to provide informed consent\n\nExclusion Criteria:\n\nA potential participant who meets any of the following criteria will be excluded from participation in this trial:\n\n1. Known or suspected heterozygous or homozygous familial hypercholesterolaemia or familial combined hyperlipidaemia\n2. Known contraindication for BA, EZE, atorvastatin, and\u002For rosuvastatin. A participant with a contraindication for atorvastatin, can be assigned to triple therapy with rosuvastatin, and vice versa.\n3. Not expected to remain on a stable dose of high intensity triple therapy for the duration of the trial.\n4. History of myocardial infarction, stroke, or peripheral artery disease (PAD), and\u002For coronary revascularisation (percutaneous coronary intervention \\[PCI\\] or coronary artery bypass grafting \\[CABG\\])\n5. Significant stenosis in the left main artery (≥50%) or proximal LAD artery (≥70%), or 3-vessel coronary artery disease (≥70% stenosis in major branches), clinically indicated for revascularisation\n6. Known significant liver disease (e.g., positive hepatitis B or hepatitis C serology) or significant hepatic dysfunction (aspartate aminotransferase \\[AST\\] or alanine aminotransferase \\[ALT\\] \\>3 x upper limit of normal \\[ULN\\])\n7. Known history of gout and\u002For uric acid levels at Screening ≥6.8 mg\u002FdL\n8. Known estimated glomerular filtration rate (eGFR) \\\u003C40 mL\u002Fmin\u002F1.73m² and\u002For receiving dialysis\n9. Active malignancy (not including non-melanoma skin cancer)\n10. Pregnant or breastfeeding\n11. Body mass index (BMI) \\>35 kg\u002Fm²\n12. Anticipated life expectancy \\\u003C52 weeks at the discretion of the local investigator\n13. Requiring emergent procedures or having any evidence of ongoing or active clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure with systolic blood pressure \\\u003C90 mmHg, severe congestive heart failure (New York Heart Association \\[NYHA\\] III or IV), or acute pulmonary oedema\n14. Suspicion of acute coronary syndrome (where acute myocardial infarction and unstable angina have not been ruled out)\n15. Complex congenital heart disease\n16. Known or suspected severe valvular heart disease or valvular heart disease anticipated to require intervention within 52 weeks at the discretion of the local investigator\n17. Cardiac arrythmia or tachycardia with significant likelihood of resulting in poor PCD-CTA image quality (especially atrial fibrillation or frequent premature beats)\n18. Intracoronary stents\n19. Prior pacemaker, internal defibrillator, or abandoned lead implantation\n20. Prosthetic heart valves\n21. Contraindications to contrast media or other medications needed for proper imaging (e.g., beta blockers and nitroglycerin)\n22. Use of any experimental or investigational drug within 40 days or 5 half-lives prior to Screening (whichever is longer), or parallel participation in another interventional study",{"count":79,"type":21},103,[55],"The overall objective of the trial is to evaluate the effect of the triple therapy consisting of bempedoic acid (BA), ezetimibe (EZE), and high-intensity atorvastatin or rosuvastatin on changes in coronary plaque burden and plaque morphology in patients with coronary atherosclerosis without significant obstructive coronary artery disease and without prior history of an ischemic vascular event.",[83,26,84],"Coronary Atherosclerosis","Hypercholesterolemia",[86,87,88,89,90,91,92],"Coronary atherosclerosis","Primary non-familial hypercholesterolaemia","Mixed dyslipidaemia","Bempedoic acid","Ezetimibe","Atorvastatin","Rosuvastatin","NOT_YET_RECRUITING","2026-03-16",{"date":96,"type":34},"2026-03-19",{"date":98,"type":21},"2026-06-01",{"date":100,"type":21},"2028-10-02",{"name":102,"class":41},"Daiichi Sankyo",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":53,"phases":113,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":70},"100623275","atlantis-trial-phospholipid-omega-3-versus-conventional-omega-3-100623275","NCT07394517","ATLANTIS Trial: Phospholipid Omega-3 Versus Conventional Omega-3","Efficacy of Phospholipid Omega-3 (Ruby-O) Versus Conventional Omega-3 on the Omega-3 Index in Patients With Mixed Dyslipidemia: A 24-Week Randomized, Double-Blind, Parallel Trial","ATLANTIS","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Adults aged 18 years or older.\n* Diagnosis of mixed dyslipidemia.\n* Fasting triglyceride levels between 135 and 499 mg\u002FdL.\n* Body mass index (BMI) ≥27 kg\u002Fm².\n* High-sensitivity C-reactive protein (hs-CRP) \\>2 mg\u002FL.\n* Stable statin therapy for at least 8 weeks prior to enrollment.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Fasting triglyceride levels ≥500 mg\u002FdL.\n* History of a recent cardiovascular event.\n* Significant hepatic or renal disease.\n* Pregnancy or breastfeeding.\n* Known allergy or hypersensitivity to fish or seafood.\n* Use of omega-3 supplements within 8 weeks prior to randomization.\n* Participation in another interventional clinical trial within 8 weeks prior to enrollment.",{"count":112,"type":21},105,[114],"NA","This study is a clinical trial designed to compare two forms of omega-3 supplements in adults with mixed dyslipidemia. Mixed dyslipidemia is a condition in which blood fat levels, such as triglycerides and cholesterol, are not within the recommended range and may increase the risk of cardiovascular disease.\n\nParticipants in this study will be randomly assigned to receive one of three study products: a phospholipid-based omega-3 supplement (Ruby-O) at a moderate dose, the same phospholipid-based omega-3 supplement at a higher dose, or a conventional omega-3 supplement in triglyceride form. All study products will be taken by mouth once daily with food for 24 weeks.\n\nThe main goal of the study is to evaluate changes in the Omega-3 Index, a blood test that reflects the amount of omega-3 fatty acids incorporated into red blood cell membranes. Additional goals include evaluating changes in blood lipid levels, markers of inflammation, blood sugar metabolism, body weight, blood pressure, treatment adherence, and safety.\n\nThis study is sponsored by the Fundación del Caribe para la Investigación Biomédica and is conducted in adults who are receiving stable statin therapy. Participation in the study is voluntary, and all participants may withdraw at any time.",[26],[29,118,119,120,121,122,123,124],"Omega -3 Index","Phospholid omega-3","Triglycerides","EPA","DHA","Dietary Suplement","Cardiovascular Risk","2026-02-06",{"date":127,"type":34},"2026-02-10",{"date":129,"type":21},"2026-03",{"date":131,"type":21},"2027-03",{"name":133,"class":134},"Fundación del Caribe para la Investigación Biomédica","OTHER",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":142,"sex":17,"minAge":143,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":53,"phases":146,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":156,"locationsCount":70},"100604696","phase-1-a-study-to-compare-to-pk-characteristics-and-safety-profiles-between-ad-117-and-ad-117a-100604696","NCT07152873","A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-117 Compared to AD-117A in Healthy Adult Volunteers Under Fed State Conditions","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"19 Years",{"count":145,"type":21},60,[147],"PHASE1","Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-117 in healthy subjects.",[26],"2025-11-27",{"date":152,"type":34},"2025-12-04",{"date":154,"type":21},"2025-12-01",{"date":129,"type":21},{"name":157,"class":41},"Addpharma Inc.",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":143,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":70},"100540290","a-study-to-evaluate-the-efficacy-and-safety-of-fixed-dose-combination-of-pitavastatinezetimib-100540290","NCT06314919","A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin\u002FEzetimib","A Multicenter, Prospective, Cohort Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin\u002FEzetimibe Under the Real-World Condition","Inclusion Criteria:\n\n* Those who taking statins or statins and ezetimibe in addition to dietary and exercise therapy for primary hypercholesterolemia or mixed hyperlipidemia\n* Those who are judged to need administration of a fixed-dose combination of pitavastatin\u002Fezetimibe for change of statin's formulation or change of statin's dose, addition of ezetimibe\n\nExclusion Criteria:\n\n* Those who are taking a fixed-dose combination of pitavastatin\u002Fezetimibe at study enrollment\n* Those with hypersensitivity reactions or relevant medical history to pitavastatin or ezetimibe\n* Those who have been administered an investigational product within 12 weeks of the enrollment date or are planning to participate in another clinical trial during this study participation period.",{"count":166,"type":21},8606,"The purpose of this study is to evaluate the efficacy and safety of fixed-Dose combination of Pitavastatin\u002FEzetimibe under the real-world condition",[169,26],"Primary Hypercholesterolemia","2025-09-10",{"date":172,"type":34},"2025-09-12",{"date":174,"type":34},"2024-03-15",{"date":176,"type":21},"2026-06",{"name":178,"class":41},"Boryung Pharmaceutical Co., Ltd",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":142,"sex":17,"minAge":143,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":53,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":70},"100591135","phase-1-the-food-effect-on-pk-characteristics-and-safety-profiles-of-pa-111-100591135","NCT06976489","The Food Effect on PK Characteristics and Safety Profiles of PA-111","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Food Effect on the Safety and the Pharmacokinetics of PA-111 in Healthy Adult Volunteers",{"count":186,"type":21},40,[147],"Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.",[26],"2025-05-09",{"date":192,"type":34},"2025-05-16",{"date":194,"type":21},"2025-05",{"date":196,"type":21},"2025-07",{"name":157,"class":41},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":142,"sex":17,"minAge":143,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":53,"phases":206,"briefSummary":188,"conditions":207,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":214,"locationsCount":70},"100587770","phase-1-a-study-to-compare-to-pk-characteristics-and-safety-profiles-between-pa-111-and-pa-111a-100587770","NCT06932705","A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of PA-111 Compared to PA-111A in Healthy Adult Volunteers Under Fed State Conditions",{"count":205,"type":21},48,[147],[26],"2025-04-10",{"date":210,"type":34},"2025-04-17",{"date":212,"type":21},"2025-04",{"date":194,"type":21},{"name":157,"class":41},{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":17,"minAge":143,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":53,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":70},"100470014","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-ad-218-100470014","NCT05400317","A Study to Evaluate the Efficacy and Safety of AD-218","A Randomized, Double-blinded, Active-controlled, Multicenter Phase 3 Clinical Trial and Open-label, Extension Study to Evaluate the Efficacy and Safety of AD-218 in Patients with Mixed Dyslipidemia","Inclusion Criteria:\n\n* A man or woman over 19 years old.\n* Sign on ICF prior to study participation\n\nExclusion Criteria:\n\n* History of Fibromyalgia, Myopathy etc (CK ≥ 2 X ULN)\n* Other exclusions applied",{"count":223,"type":21},520,[55],"The purpose of this study is to evaluate the efficacy and safety of AD-218",[26],"2025-02-03",{"date":229,"type":34},"2025-02-05",{"date":231,"type":34},"2022-07-27",{"date":233,"type":21},"2026-06-30",{"name":157,"class":41}]